Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
In recent years, the treatment landscape of urothelial carcinoma has significantly changed due to the introduction of immune checkpoint inhibitors (ICIs), which are the standard of care for second-line treatment and first-line platinum-ineligible patients with advanced disease. Despite the overall s...
Enregistré dans:
Auteurs principaux: | Sara Elena Rebuzzi, Giuseppe Luigi Banna, Veronica Murianni, Alessandra Damassi, Emilio Francesco Giunta, Filippo Fraggetta, Ugo De Giorgi, Richard Cathomas, Pasquale Rescigno, Matteo Brunelli, Giuseppe Fornarini |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/fa29ae1e6f13459d8ecd55cb63cd1b64 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer
par: Guangdi Chu, et autres
Publié: (2021) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021) -
Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
par: Mencinger Marina, et autres
Publié: (2021) -
A review on the evolution of immunotherapy in bladder carcinoma
par: Milena Gulinac, et autres
Publié: (2020) -
Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma
par: Shuo Hong, et autres
Publié: (2021)